Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant
December 23 2021 - 8:03AM
Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop
synthetic biology systems, today announced the release of a new
full-length synthetic genome of the SARS-CoV-2 virus for the highly
mutated and contagious Omicron variant (B.1.1.529 lineage). Omicron
has been identified as a Variant of Concern by WHO and is spreading
more rapidly than any other previous variant of SARS-CoV-2. The
genome was built with the company’s BioXp™ 3250 system, a fully
automated synthetic biology benchtop workstation for rapid,
accurate, and reproducible writing of DNA and mRNA.
“The Codex DNA team applauds the excellent work done by
scientists in South Africa to identify and quickly characterize the
latest SARS-CoV-2 variant of concern, and we aim to honor their
efforts by releasing this new synthetic genome to expand research
access to labs around the world,” said Todd R. Nelson, PhD, CEO of
Codex DNA. “This synthetic version of Omicron reflects our
continued commitment to provide helpful tools and resources to
scientists fighting the COVID-19 pandemic.”
With the Omicron variant, Codex DNA offers a full catalogue of
14 SARS-CoV-2 synthetic genomes as well as custom-made SARS-CoV-2
genomes that are used to support researchers in their search for
solutions to fight specific variants. In addition, Codex DNA offers
custom DNA synthesis services to address the global pandemic. For
customers interested in alternative variants to SARS-CoV-2, Codex
DNA provides a wide range of synthetic controls that enable
scientists to confidently verify and validate assays without the
need for clinical virus samples.
All synthetic genomes produced by Codex DNA are manufactured in
the United States and are available to researchers who pass a
rigorous biosecurity screening process to ensure their responsible
use. For more information on Codex DNA’s portfolio of tools for
addressing SARS-CoV-2, please visit
https://codexdna.com/products/coronavirus/.
About Codex DNA
Codex DNA is empowering scientists with the ability to create
novel, synthetic biology-enabled solutions for many of humanity’s
greatest challenges. As inventors of the industry-standard Gibson
Assembly® method and the first commercial automated benchtop DNA
and mRNA synthesis system, Codex DNA is enabling rapid, accurate,
and reproducible writing of DNA and mRNA for numerous downstream
markets. The company’s award-winning BioXp™ system consolidates,
automates, and optimizes the entire synthesis, cloning, and
amplification workflow. As a result, it delivers virtually
error-free synthesis of DNA/RNA at scale within days and hours
instead of weeks or months. Scientists around the world are using
the technology in their own laboratories to accelerate the
design-build-test paradigm for novel, high-value products for
precision medicine, biologics drug discovery, vaccine and
therapeutic development, genome editing, and cell and gene therapy.
Codex DNA is a public company based in San Diego. For more
information, visit codexdna.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Codex DNA’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Codex DNA’s actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. These
statements include but are not limited to statements regarding
Codex DNA’s ability to generate synthetic SARS-CoV-2 genomes and
their usefulness in COVID-19 diagnostics and therapeutic discovery.
These and other risks are described more fully in Codex DNA’s
filings with the Securities and Exchange Commission (“SEC”) and
other documents that Codex DNA subsequently files with the SEC from
time to time. Except to the extent required by law, Codex DNA
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contact:Richard LepkeDirector of Investor Relations(619)
840-5392RichardL@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2023 to Jul 2024